Dr. Reddy’s, CutisPharma announce API supply, joint development partnerships

WILMINGTON, Mass. — Dr. Reddy’s Laboratories and specialty pharmaceutical company CutisPharma announced Tuesday agreements for active pharmaceutical ingredient (API) supply and joint development as a way to advance several of CutisPharma’s research and development programs. 

 

“This partnership has significant strategic benefits for both parties,” CutisPharma CEO Dr. Neal Muni said. “Dr. Reddy's Laboratories’ breadth of expertise and international infrastructure provide great synergy to CutisPharma's own R&D and commercial organizations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards New Drug Application (NDA) filings.”

 

CutisPharma recently opened a new manufacturing center at its headquarters and the partnership will see the acceleration of three drugs in its pipeline toward approval by the Food and Drug Administration. 

 

“We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem,” Dr. Reddy’s VP and global head of CPS business Deepak Sapra said. “The partnership with CutisPharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”